Navigation Links
Hadasit Bio-Holdings Ltd. to Present at the Third Annual Connecticut-Israel Technology Summit

JERUSALEM, June 5, 2013 /PRNewswire/ -- Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a publicly traded portfolio of biotech companies, based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced that Mr. Ophir Shahaf , Chief Executive Officer, will be presenting at the third annual Connecticut-Israel Technology Summit on June 12th at The Oakdale Theater in Wallingford, CT. 

Mr. Shahaf will discuss the six current portfolio companies in Hadasit Bio-Holdings as part of the "Introductions of Israeli Biomed Companies" segment of the conference.  In addition to Hadasit Bio-Holdings, there are currently 20 community leaders, businesses, and institutions slated to participate, including Hartford Hospital, Gartner, Briefcam, The Hartford, United Technologies Corporation, the University of Connecticut, the Department of Economic and Community Development, and the Binational Industrial Research and Development Foundation.

"I am eager and excited to present our story to this targeted group of businesses and individuals looking to advance partnerships with Israeli companies," said Mr. Shahaf.  "Our unique business model and relationship to the Hadassah Hospitals in Israel has afforded us the opportunity to obtain world-class scientific research, turn this research into fully functioning companies and then further advance the companies through the help of our public company vehicle.  I look forward to discussing our story and potential strategic partnerships with the attendees of the conference."

The conference, which begins at 11 a.m. and ends at 6 p.m., will focus on building partnerships between Israeli companies and Connecticut. The organizers' goal is to encourage Israeli companies to locate their U.S. offices in Connecticut and to assist existing businesses in the state in partnering with Israeli technology companies. Part of the June 12th summit will be devoted to group roundtable discussions and other networking opportunities. Four companies will be recognized for successfully forming partnerships.

For more information about Hadasit Bio-Holdings please visit:

Investor Contact:
KCSA Strategic Communications
Phil Carlson / Josh Dver
212.896.1233 / 1239 /

SOURCE Hadasit Bio-Holdings Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
2. KAHR Medical, a Hadasit Bio-Holdings Portfolio Company, to Raise $2.6 Million
3. Hadasit Bio-Holdings Interviewed by Wall Street Reporter
4. Hadasit Bio-Holdings Ltd. Portfolio Companies - ProtAb Ltd. and KAHR Medical Ltd. to Receive NIS 10.7 Million (Over $2.8 Million USD) in Additional Government Grants
5. Hadasit Bio-Holdings CEO Letter to Shareholders
6. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
7. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
8. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
10. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
11. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
Post Your Comments:
(Date:6/24/2016)... Brooklyn, NY (PRWEB) , ... June 24, 2016 , ... ... 15mm, machines such as the Cary 5000 and the 6000i models are higher end ... height is the height of the spectrophotometer’s light beam from the bottom of the ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in ... Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio ... practical tips, tools, and strategies for clinical researchers. , “The landscape of how ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... , June 23, 2016 A person commits a ... crime scene to track the criminal down. An ... Food and Drug Administration (FDA) uses DNA evidence to track ... Sound far-fetched? It,s not. The FDA has increasingly ... support investigations of foodborne illnesses. Put as simply as possible, ...
Breaking Biology Technology:
(Date:6/21/2016)... , June 21, 2016 NuData ... the new role of principal product architect and ... the director of customer development. Both will report ... technical officer. The moves reflect NuData,s strategic growth ... response to high customer demand and customer focus ...
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/9/2016)... June 9, 2016  Perkotek an innovation leader in attendance control systems is proud ... work hours, for employers to make sure the right employees are actually signing in, ... ... ... ...
Breaking Biology News(10 mins):